| __timestamp | Neurocrine Biosciences, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 504755000 |
| Thursday, January 1, 2015 | 32480000 | 838526000 |
| Friday, January 1, 2016 | 68081000 | 1177697000 |
| Sunday, January 1, 2017 | 169906000 | 1320433000 |
| Monday, January 1, 2018 | 248932000 | 1556200000 |
| Tuesday, January 1, 2019 | 354100000 | 1834800000 |
| Wednesday, January 1, 2020 | 433300000 | 1346000000 |
| Friday, January 1, 2021 | 583300000 | 1824900000 |
| Saturday, January 1, 2022 | 752700000 | 2115900000 |
| Sunday, January 1, 2023 | 887600000 | 2631300000 |
| Monday, January 1, 2024 | 1007200000 | 2954400000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A expenses surged by over 400%, peaking at approximately $2.63 billion in 2023. This reflects their aggressive expansion and strategic investments. In contrast, Neurocrine's SG&A expenses grew by nearly 500%, reaching around $887 million in the same year, indicating a robust scaling strategy. The data highlights Regeneron's consistent dominance in operational spending, yet Neurocrine's rapid growth rate suggests a competitive edge in agility. As these biotech titans continue to innovate, understanding their financial strategies offers invaluable insights into their market positioning and future potential.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Neurocrine Biosciences, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Regeneron Pharmaceuticals, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. and Galapagos NV: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Celldex Therapeutics, Inc.